Immunologic and Clinical Responses to Rituximab in a Child With Opsoclonus-Myoclonus Syndrome

Pranzatelli, Michael R.; Tate, Elizabeth D.; Travelstead, Anna L.; Longee, Darryl C.

doi:10.1542/peds.2004-0845

Cited by 65 publications

(32 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IgG and IgA titers showed no statistically significant changes [Pranzatelli et al 2006]. Other case reports also confirm the benefit of rituximab in OMS children including a 3½-year-old patient with ganglioneuroblastoma [Bell et al 2008;Burke and Cohn, 2008;Corapcioglou et al 2008;Pranzatelli et al 2005].…”

Section: Opsoclonusmyoclonus Syndromementioning

confidence: 91%

Practical considerations on the use of rituximab in autoimmune neurological disorders

Kosmidis

Dalakas

2010

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Rituximab (Mabthera, Rituxan) is a chimeric human/murine monoclonal antibody against CD-20 surface antigen expressed on B-cells. Rituximab, by causing B-cell depletion, appears to be effective in several autoimmune disorders; it has been approved for rheumatoid arthritis and is a promising new agent in the treatment of several autoimmune neurological disorders. A controlled study in patients with relapsing remitting multiple sclerosis has shown that rituximab significantly reduces the number of new MRI lesions and improves clinical outcome; it also showed some promise in a subset of patients with primary progressive MS. The drug is also effective in a number of patients with Devic's disease, myasthenia gravis, autoimmune neuropathies, and inflammatory myopathies. The apparent effectiveness of rituximab has moved B-cells into the center stage of clinical and laboratory investigation of autoimmune neurological disorders. We review the evidence-based effectiveness of rituximab in neurological disorders based on controlled trials and anecdotal reports, including our own experience, and address the immunobiology of B-cells in autoimmune central nervous system (CNS) and peripheral nervous system (PNS) disorders. In addition, we provide practical guidelines on how best to use this drug in clinical practice and highlight its potential toxicity.

show abstract

Section: Opsoclonusmyoclonus Syndromementioning

confidence: 91%

Practical considerations on the use of rituximab in autoimmune neurological disorders

Kosmidis

Dalakas

2010

Ther Adv Neurol Disord

View full text Add to dashboard Cite

show abstract

“…Pranzatelli et al further reported response to treatment with rituximab which is an anti-CD 20 monoclonal antibody. The clinical improvement correlated with reduction of B lymphocytes in CSF 33–35…”

Section: Pathology and Pathogenesismentioning

confidence: 81%

The opsoclonus-myoclonus syndrome

Sahu

Prasad

2011

Practical Neurology

View full text Add to dashboard Cite

The opsoclonus–myoclonus syndrome is a rare and distinct neurological disorder characterised by rapid multidirectional conjugate eye movements (opsoclonus), myoclonus and ataxia, along with behavioural changes in adults and irritability in children. Sometimes it is due to a self-limiting presumed para-infectious brainstem encephalitis but it may also represent a non-metastatic manifestation of neuroblastoma in children and small cell carcinoma of the lung in adults. In this article, we will describe the clinical features, diagnosis, pathogenesis and management.

show abstract

“…Em alguns casos, há necessidade de manutenção da terapia por vários meses (19) . A gamaglobulina intravenosa, a azatioprina, a ciclosfosfamida, as sessões de plasmaferese e, recentemente, o rituximabe são alternativas terapêuticas para casos refratários (2,9,23,24) . Em nosso meio, essas alternativas terapêuticas ainda são limitadas.…”

Section: Discussionunclassified

Síndrome de Kinsbourne manifestando-se com quadro de encefalite pós-viral

Andrade

Troster

Cypel

2011

Rev. paul. pediatr.

View full text Add to dashboard Cite

OBJETIVO: Descrever um caso de síndrome de Kinsbourne manifestando-se com quadro de encefalite pós-viral e rever a da literatura. DESCRIÇÃO DO CASO: Criança do sexo feminino, dois anos e seis meses, encaminhada de outro serviço com história de ataxia, irritabilidade e dificuldades articulatórias na fala após episódio prodrômico de febre, lesões de pele e mucosa. Com hipótese de encefalite pós-viral, a avaliação clínica evidenciou quadro de síndrome opsoclônus-mioclonia-ataxia ou síndrome de Kinsbourne. Foi afastada a associação de neuroblastoma oculto e iniciada terapêutica com corticosteroide. Durante internação e acompanhamento ambulatorial, houve regressão progressiva e normalização do quadro clínico e neurológico inicial. COMENTÁRIOS: Apesar de se tratar de uma doença rara, o diagnóstico de síndrome de Kinsbourne deve ser reconhecido pelos pediatras e intensivistas, com objetivo de instituir tratamento específico precoce, embora com resultados variáveis, sendo fundamental a exclusão de neuroblastoma oculto.

show abstract

Immunologic and Clinical Responses to Rituximab in a Child With Opsoclonus-Myoclonus Syndrome

Abstract: ABBREVIATIONS. OMS, opsoclonus-myoclonus syndrome; CSF, cerebrospinal fluid; NK, natural killer; IVIg, intravenously administered immunoglobulin; Ig, immunoglobulin.

Cited by 65 publications

References 25 publications

Practical considerations on the use of rituximab in autoimmune neurological disorders

Practical considerations on the use of rituximab in autoimmune neurological disorders

The opsoclonus-myoclonus syndrome

Síndrome de Kinsbourne manifestando-se com quadro de encefalite pós-viral

Contact Info

Product

Resources

About